@article{3812fab062dd40c098e4d4d3436eab48,
title = "New Drugs on the Horizon for Functional and Motility Gastrointestinal Disorders",
author = "Michael Camilleri",
note = "Funding Information: Funding Dr Camilleri receives funding for studies on irritable bowel syndrome and gastroparesis from the National Institutes of Health (grants R01-DK115950 and R01-DK122280). Funding Information: Conflicts of interest Dr Camilleri received research grants from Arena, Novartis, Vanda, and Takeda for studies on olorinab, tropefixor, tradipitant, and felcisetrag, respectively. He does not receive any personal financial benefit from the interactions with those companies. Funding Dr Camilleri receives funding for studies on irritable bowel syndrome and gastroparesis from the National Institutes of Health (grants R01-DK115950 and R01-DK122280).",
year = "2021",
month = sep,
doi = "10.1053/j.gastro.2021.04.079",
language = "English (US)",
volume = "161",
pages = "761--764",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "3",
}